The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe.
Cancer screening
Colorectal cancer
Miscrosimulation models
Online screening evaluation tool
Journal
Preventive medicine reports
ISSN: 2211-3355
Titre abrégé: Prev Med Rep
Pays: United States
ID NLM: 101643766
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
15
09
2020
revised:
31
03
2021
accepted:
08
04
2021
entrez:
24
5
2021
pubmed:
25
5
2021
medline:
25
5
2021
Statut:
epublish
Résumé
Aiming to support European countries in improving their breast, cervical, and colorectal cancer (CRC) screening programmes, the EU-TOPIA consortium has developed an online user-friendly tool (the EU-TOPIA evaluation tool; https://miscan.eu-topia.org) based on the Microsimulation Screening Analysis (MISCAN) model. We designed an online platform that allows stakeholders to use their country-specific data (demographic, epidemiological, and cancer screening information) to quantify future harms and benefits of different cancer screening scenarios in their country. Current cancer screening programmes and impacts of potential changes in screening protocols (such as extending target ages or increasing screening attendance) can be simulated. Results are scaled to the country-specific population. To illustrate the tool, we used the tool to simulate two different CRC screening scenarios in the Netherlands: biennial fecal immunochemical testing (FIT) in ages 55-75 and colonoscopy every ten years in ages 55-75. Data from the Dutch screening programme was used to inform both scenarios. A total of 482,700 CRC cases and 178,000 CRC deaths were estimated in the Netherlands with FIT screening (for individuals aged 40-100 years, 2018-2050), with 47.3 million FITs performed (1.92 million positives of which 1.64 million adhered to diagnostic colonoscopy). With colonoscopy screening, CRC incidence and mortality were, respectively, up to 17% and 14% lower than in the current FIT screening programme, requiring, however, a colonoscopy demand that was 7-fold higher. Our study presents an essential online tool for stakeholders and medical societies to quantify estimates of benefits and harms of early cancer detection in Europe.
Sections du résumé
BACKGROUND
BACKGROUND
Aiming to support European countries in improving their breast, cervical, and colorectal cancer (CRC) screening programmes, the EU-TOPIA consortium has developed an online user-friendly tool (the EU-TOPIA evaluation tool; https://miscan.eu-topia.org) based on the Microsimulation Screening Analysis (MISCAN) model.
METHODS
METHODS
We designed an online platform that allows stakeholders to use their country-specific data (demographic, epidemiological, and cancer screening information) to quantify future harms and benefits of different cancer screening scenarios in their country. Current cancer screening programmes and impacts of potential changes in screening protocols (such as extending target ages or increasing screening attendance) can be simulated. Results are scaled to the country-specific population. To illustrate the tool, we used the tool to simulate two different CRC screening scenarios in the Netherlands: biennial fecal immunochemical testing (FIT) in ages 55-75 and colonoscopy every ten years in ages 55-75. Data from the Dutch screening programme was used to inform both scenarios.
RESULTS
RESULTS
A total of 482,700 CRC cases and 178,000 CRC deaths were estimated in the Netherlands with FIT screening (for individuals aged 40-100 years, 2018-2050), with 47.3 million FITs performed (1.92 million positives of which 1.64 million adhered to diagnostic colonoscopy). With colonoscopy screening, CRC incidence and mortality were, respectively, up to 17% and 14% lower than in the current FIT screening programme, requiring, however, a colonoscopy demand that was 7-fold higher.
CONCLUSIONS
CONCLUSIONS
Our study presents an essential online tool for stakeholders and medical societies to quantify estimates of benefits and harms of early cancer detection in Europe.
Identifiants
pubmed: 34026466
doi: 10.1016/j.pmedr.2021.101392
pii: S2211-3355(21)00082-6
pmc: PMC8122113
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101392Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
JAMA. 2016 Jun 21;315(23):2595-609
pubmed: 27305518
BJOG. 2021 Feb;128(3):573-582
pubmed: 32638462
BMJ. 2019 Oct 2;367:l5383
pubmed: 31578177
Eur J Cancer. 2020 Mar;127:224-235
pubmed: 31932176
Eur J Cancer. 2020 Mar;127:191-206
pubmed: 31932175
Gastroenterology. 2017 Mar;152(4):767-775.e2
pubmed: 27890769
Curr Oncol. 2017 Dec;24(6):401-406
pubmed: 29270052
J Med Screen. 2019 Sep;26(3):120-126
pubmed: 30621498
Health Serv Res. 2015 Jun;50(3):768-89
pubmed: 25324198
BJU Int. 2017 Apr;119(4):560-566
pubmed: 27222299
J Med Screen. 2020 Nov 5;:969141320968598
pubmed: 33153369
MDM Policy Pract. 2021 Jan 29;6(1):2381468320984974
pubmed: 33598546
Eur J Cancer. 2020 Mar;127:207-223
pubmed: 31980322
Lung Cancer. 2018 Jul;121:61-69
pubmed: 29858029
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
MDM Policy Pract. 2017 Jul;2:
pubmed: 29376135
JCO Clin Cancer Inform. 2018 Dec;2:1-11
pubmed: 30652551
Radiology. 2020 Oct;297(1):40-48
pubmed: 32749212
Gynecol Oncol. 2021 Jan;160(1):118-127
pubmed: 33199028